| PEA | Palmitoylethanolamide |
| eCB | Endocannabinoid |
| NAE | N-acyl-ethanolamine |
| PPARα | Peroxisome proliferator-activated receptor-α |
| GPR55 | G protein-coupled receptor 55 |
| GPR119 | G protein-coupled receptor 119 |
| CB1 | Cannabinoid receptor 1 |
| CB2 | Cannabinoid receptor 1 |
| AEA | Anandamide |
| TRPV1 | Transient receptor potential vanilloid 1 |
| MC | Mast cells |
| ALIA | Autacoid Local Inflammation Antagonism |
| TNF-α | Tumour necrosis factor αlpha |
| IL | Interleukin |
| ICAM-1 | Intercellular Adhesion Molecule 1 |
| NF-κB | Nuclear factor kappa B |
| CNS | Central nervous system |
| FAAH | Fatty acid amide hydrolase |
| GALT | Gut-associated lymphoid tissue |
| GIT | Gastrointestinal tract |
| CAD | Contact allergic dermatitis |
| AD | Alzheimer’s disease |
| PD | Parkinson’s Disease |
| TBI | Traumatic brain injury |
| ASD | Autism spectrum disorder |
| Bcl-2 | B-cell lymphoma 2 |
| BAX | Bcl-2-associated X protein |
| Akt | Protein kinase B |
| mTOR | Mechanistic target of rapamycin |
| P70S6k | Ribosomal protein S6 kinase beta-1 |
| PTSD | Post-traumatic stress disorder |
| CDR | Cell Danger Response |
| BDNF | Brain-derived neurotrophic factor |
| GDNF | Glial cell line-derived neurotrophic factor |
| GBA | Gut–brain axis |
| LPS | Lipopolysaccharides |
| BBB | Blood–brain barrier |
| TTH | Tension-type headaches |
| NSAIDs | Non-steroidal anti-inflammatory drugs |
| PGF2α | Prostaglandin F2-α |
| PGE2 | Prostaglandin E2 |
| OA | Osteoarthritis |
| TMJ | Temporomandibular joint |
| WOMAC | Western Ontario and McMaster Universities Osteoarthritis Index |
| EIMD | Exercise-induced muscle damage |
| DOMS | Delayed onset muscle soreness |
| CBD | Cannabidiol |
| CTS | Carpal tunnel syndrome |